Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2018
Date: 2019-02-21
Institutions: Standing Committee of the EFTA States
Subjects: EFTA countries, European Economic Area, free movement of goods, market approval, medicinal product, withdrawal from the market








C_2019068EN.01000501.xml










21.2.2019   


EN


Official Journal of the European Union


C 68/5






Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2018
(2019/C 68/06)

Subcommittee I on the free movement of goods


To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January — 30 June 2018, at their meeting on 26 October 2018:






Annex I


List of new marketing authorisations




Annex II


List of renewed marketing authorisations




Annex III


List of extended marketing authorisations




Annex IV


List of withdrawn marketing authorisations




Annex V


List of suspended marketing authorisations








ANNEX I
List of new marketing authorisations
The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January — 30 June 2018:








EU-Number


Product


Country


Date of authorisation




EU/1/13/901


Sirturo


Liechtenstein


30.4.2018




EU/1/15/1047


Blincyto


Liechtenstein


30.6.2018




EU/1/17/1173


Lokelma


Iceland


26.3.2018




EU/1/17/1173


Lokelma


Liechtenstein


30.4.2018




EU/1/17/1173


Lokelma


Norway


16.4.2018




EU/1/17/1231


Ocrevus


Iceland


11.1.2018




EU/1/17/1231


Ocrevus


Liechtenstein


28.2.2018




EU/1/17/1231


Ocrevus


Norway


17.1.2018




EU/1/17/1234


Tremfya


Norway


18.1.2018




EU/1/17/1244


Tacforius


Iceland


5.1.2018




EU/1/17/1244


Tacforius


Norway


3.1.2018




EU/1/17/1245


Prevymis


Iceland


19.1.2018




EU/1/17/1245


PREVYMIS


Liechtenstein


28.2.2018




EU/1/17/1245


PREVYMIS


Norway


5.2.2018




EU/1/17/1246


Mvasi


Iceland


24.1.2018




EU/1/17/1246


Mvasi


Norway


30.1.2018




EU/1/17/1247


Adynovi


Iceland


11.1.2018




EU/1/17/1247


ADYNOVI


Liechtenstein


28.2.2018




EU/1/17/1247


ADYNOVI


Norway


19.1.2018




EU/1/17/1248


Darunavir Krka d.d.


Iceland


24.1.2018




EU/1/17/1248


Darunavir Krka d.d.


Norway


14.2.2018




EU/1/17/1249


Darunavir Krka


Iceland


26.1.2018




EU/1/17/1249


Darunavir Krka


Liechtenstein


28.2.2018




EU/1/17/1249


Darunavir Krka


Norway


14.2.2018




EU/1/17/1250


Rubraca


Iceland


5.6.2018




EU/1/17/1250


Rubraca


Liechtenstein


30.6.2018




EU/1/17/1250


Rubraca


Norway


31.5.2018




EU/1/17/1251


Ozempic


Iceland


15.2.2018




EU/1/17/1251


Ozempic


Liechtenstein


28.2.2018




EU/1/17/1251


Ozempic


Norway


14.2.2018




EU/1/17/1252


Fasenra


Iceland


11.1.2018




EU/1/17/1252


Fasenra


Liechtenstein


28.2.2018




EU/1/17/1252


Fasenra


Norway


16.1.2018




EU/1/17/1253


Fulvestrant Mylan


Iceland


12.2.2018




EU/1/17/1253


Fulvestrant Mylan


Liechtenstein


28.2.2018




EU/1/17/1253


Fulvestrant Mylan


Norway


29.5.2018




EU/1/17/1254


Jorveza


Iceland


15.1.2018




EU/1/17/1254


Jorveza


Liechtenstein


28.2.2018




EU/1/17/1254


Jorveza


Norway


19.1.2018




EU/1/17/1255


Intrarosa


Iceland


7.2.2018




EU/1/17/1255


Intrarosa


Liechtenstein


28.2.2018




EU/1/17/1256


Anagrelide Mylan


Iceland


26.2.2018




EU/1/17/1256


Anagrelid Mylan


Liechtenstein


28.2.2018




EU/1/17/1256


Anagrelide Mylan


Norway


27.2.2018




EU/1/17/1257


Herzuma


Iceland


15.2.2018




EU/1/17/1257


Herzuma


Liechtenstein


28.2.2018




EU/1/17/1257


Herzuma


Norway


14.2.2018




EU/1/17/1258


Lamzede


Iceland


11.4.2018




EU/1/17/1258


Lamzede


Liechtenstein


30.4.2018




EU/1/17/1258


Lamzede


Norway


16.4.2018




EU/1/17/1260


Alkindi


Iceland


15.2.2018




EU/1/17/1260


Alkindi


Liechtenstein


28.2.2018




EU/1/17/1260


Alkindi


Norway


2.3.2018




EU/1/17/1261


Alofisel


Iceland


10.4.2018




EU/1/17/1261


Alofisel


Liechtenstein


30.4.2018




EU/1/17/1261


Alofisel


Norway


9.4.2018




EU/1/17/1262


Crysvita


Iceland


26.2.2018




EU/1/17/1262


CRYSVITA


Liechtenstein


30.4.2018




EU/1/17/1262


CRYSVITA


Norway


9.4.2018




EU/1/17/1263


Efavirenz/Emtricitabine/Tenofovir disoproxil Krka


Iceland


15.2.2018




EU/1/17/1263


Efavirenz/Emtricitabine/Tenofovir disoproxil Krka


Liechtenstein


28.2.2018




EU/1/17/1263


Efavirenz/Emtricitabine/Tenofovir disoproxil Krka


Norway


14.2.2018




EU/1/18/1265


Segluromet


Iceland


10.4.2018




EU/1/18/1265


Segluromet


Liechtenstein


30.4.2018




EU/1/18/1265


Segluromet


Norway


9.4.2018




EU/1/18/1266


Steglujan


Iceland


11.4.2018




EU/1/18/1266


Steglujan


Liechtenstein


30.4.2018




EU/1/18/1266


Steglujan


Norway


7.4.2018




EU/1/18/1267


Steglatro


Iceland


10.4.2018




EU/1/18/1267


Steglatro


Liechtenstein


30.4.2018




EU/1/18/1267


Stegatro


Norway


9.4.2018




EU/1/18/1269


Alpivab


Iceland


11.5.2018




EU/1/18/1269


Alpivab


Liechtenstein


30.4.2018




EU/1/18/1269


Alpivab


Norway


26.6.2018




EU/1/18/1270


Semglee


Iceland


10.4.2018




EU/1/18/1270


Semglee


Liechtenstein


30.4.2018




EU/1/18/1270


Semglee


Norway


23.5.2018




EU/1/18/1271


Hemlibra


Iceland


2.3.2018




EU/1/18/1271


Hemlibra


Liechtenstein


28.2.2018




EU/1/18/1271


Hemlibra


Norway


8.3.2018




EU/1/18/1272


Shingrix


Iceland


26.3.2018




EU/1/18/1272


Shingrix


Liechtenstein


30.4.2018




EU/1/18/1272


Shingrix


Norway


5.4.2018




EU/1/18/1273


Prasugrel Mylan


Iceland


29.5.2018




EU/1/18/1273


Prasugrel Mylan


Liechtenstein


30.6.2018




EU/1/18/1274


Trydonis


Iceland


23.5.2018




EU/1/18/1274


Trydonis


Liechtenstein


30.6.2018




EU/1/18/1274


Trydonis


Norway


28.5.2018




EU/1/18/1275


Riarify


Iceland


23.5.2018




EU/1/18/1275


Riarify


Liechtenstein


30.6.2018




EU/1/18/1277


Mylotarg


Iceland


16.5.2018




EU/1/18/1277


Mylotarg


Liechtenstein


30.6.2018




EU/1/18/1277


Mylotarg


Norway


4.5.2018




EU/1/18/1279


AMGLIDIA


Iceland


5.6.2018




EU/1/18/1279


AMGLIDIA


Liechtenstein


30.6.2018




EU/1/18/1279


AMGLIDIA


Norway


26.6.2018




EU/1/18/1280


Zessly


Iceland


4.6.2018




EU/1/18/1280


Zessly


Liechtenstein


30.6.2018




EU/1/18/1280


Zessly


Norway


15.6.2018




EU/1/18/1281


Kanjinti


Iceland


29.5.2018




EU/1/18/1281


KANJINTI


Liechtenstein


30.6.2018




EU/1/18/1281


KANJINTI


Norway


24.5.2018




EU/1/18/1282


Juluca


Iceland


29.5.2018




EU/1/18/1282


Juluca


Liechtenstein


30.6.2018




EU/1/18/1282


Juluca


Norway


24.5.2018




EU/1/18/1283


Pemetrexed Krka


Iceland


30.5.2018




EU/1/18/1283


Pemetrexed Krka


Liechtenstein


30.6.2018




EU/1/18/1283


Pemetrexed Krka


Norway


31.5.2018




EU/1/18/1289


Biktarvy


Iceland


28.6.2018




EU/1/18/1289


Bictarvy


Liechtenstein


30.6.2018




EU/1/18/1289


Biktarvy


Norway


27.6.2018




EU/2/17/216


Oxybee


Iceland


26.3.2018




EU/2/17/216


Oxybee


Liechtenstein


30.4.2018




EU/2/17/216


Oxybee


Norway


20.4.2018




EU/2/17/219


Rabitec


Iceland


4.1.2018




EU/2/17/219


Rabitec


Liechtenstein


28.2.2018




EU/2/17/219


Rabitec


Norway


9.1.2018




EU/2/17/220


MiPet Easecto


Iceland


26.2.2018




EU/2/17/220


MiPet Easecto


Norway


20.4.2018




EU/2/17/221


GALLIPRANT


Iceland


17.1.2018




EU/2/17/221


GALLIPRANT


Liechtenstein


28.2.2018




EU/2/17/221


GALLIPRANT


Norway


24.1.2018




EU/2/17/222


Clevor


Iceland


3.5.2018




EU/2/17/222


Clevor


Liechtenstein


30.4.2018




EU/2/17/222


Clevor


Norway


7.5.2018




EU/2/17/223


Suvaxyn Circo


Iceland


12.4.2018




EU/1/17/223


Suvaxyn Circo


Liechtenstein


28.2.2018




EU/2/17/223


Suvaxyn Circo


Norway


13.2.2018




EU/2/18/224


Bravecto Plus


Iceland


28.5.2018




EU/2/18/224


Bravecto Plus


Liechtenstein


30.6.2018




EU/2/18/224


Bravecto Plus


Norway


1.6.2018




EU/2/18/225


Dany’s BienenWohl


Iceland


21.6.2018




EU/2/18/225


Dany’s BienenWohl


Liechtenstein


30.6.2018




EU/2/18/225


Dany’s BienenWohl


Norway


29.6.2018









ANNEX II
List of renewed marketing authorisations
The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January — 30 June 2018:








EU-Number


Product


Country


Date of authorisation




EU/1/08/442


Pradaxa


Iceland


12.1.2018




EU/1/08/442


Pradaxa


Liechtenstein


28.2.2018




EU/1/08/442


Pradaxa


Norway


18.1.2018




EU/1/08/443


Thalidomide Celgene


Iceland


14.2.2018




EU/1/08/443


Thalidomide Celgene


Liechtenstein


28.2.2018




EU/1/08/443


Thalidomide Celgene


Norway


6.3.2018




EU/1/08/448


Mycamine


Iceland


26.2.2018




EU/1/08/472


Xarelto


Iceland


30.5.2018




EU/1/08/472


Xarelto


Liechtenstein


30.6.2018




EU/1/08/472


Xarelto


Norway


21.6.2018




EU/1/10/628


Votrient


Iceland


18.1.2018




EU/1/10/628


Votrient


Liechtenstein


28.2.2018




EU/1/10/628


Votrient


Norway


17.1.2018




EU/1/11/749


Caprelsa


Iceland


15.2.2018




EU/1/11/749


Caprelsa


Liechtenstein


28.2.2018




EU/1/11/749


Caprelsa


Norway


15.2.2018




EU/1/12/764


Pixuvri


Iceland


11.4.2018




EU/1/12/764


Pixuvri


Liechtenstein


30.4.2018




EU/1/12/764


Pixuvri


Norway


4.4.2018




EU/1/13/813


Perjeta


Norway


3.1.2018




EU/1/13/817


Actelsar HCT


Iceland


5.1.2018




EU/1/13/817


Actelsar HCT


Norway


4.1.2018




EU/1/13/818


Bosulif


Iceland


26.2.2018




EU/1/13/818


Bosulif


Liechtenstein


28.2.2018




EU/1/13/818


Bosulif


Norway


21.2.2018




EU/1/13/820


Marixino


Iceland


24.1.2018




EU/1/13/820


Marixino


Liechtenstein


28.2.2018




EU/1/13/820


Marixino


Norway


14.2.2018




EU/1/13/821


Tolucombi


Iceland


29.1.2018




EU/1/13/821


Tolucombi


Norway


20.3.2018




EU/1/13/822


PHEBURANE


Iceland


10.4.2018




EU/1/13/822


PHEBURANE


Liechtenstein


30.4.2018




EU/1/13/822


PHEBURANE


Norway


16.4.2018




EU/1/13/823


Adasuve


Iceland


24.1.2018




EU/1/13/823


Adasuve


Norway


16.3.2018




EU/1/13/824


Nemdatine


Iceland


29.1.2018




EU/1/13/825


Imatinib Actavis


Iceland


12.1.2018




EU/1/13/825


Imatinib Actavis


Liechtenstein


28.2.2018




EU/1/13/825


Imatinib Actavis


Norway


12.1.2018




EU/1/13/826


Memantine LEK


Iceland


29.1.2018




EU/1/13/827


Memantine Mylan


Iceland


29.1.2018




EU/1/13/828


Hexacima


Iceland


29.1.2018




EU/1/13/829


Hexyon


Iceland


29.1.2018




EU/1/13/829


Hexyon


Liechtenstein


30.6.2018




EU/1/13/829


Hexyon


Norway


12.2.2018




EU/1/13/830


Stribild


Iceland


16.5.2018




EU/1/13/830


Stribild


Norway


7.5.2018




EU/1/13/832


Stayveer


Iceland


24.1.2018




EU/1/13/832


Stayveer


Liechtenstein


28.2.2018




EU/1/13/832


Stayveer


Norway


24.1.2018




EU/1/13/835


Voriconazole Accord


Iceland


14.2.2018




EU/1/13/835


Voriconazol Accord


Liechtenstein


28.2.2018




EU/1/13/835


Voriconazole Accord


Norway


2.3.2018




EU/1/13/836


Memantine ratiopharm


Iceland


3.5.2018




EU/1/13/836


Memantin ratiopharm


Liechtenstein


30.4.2018




EU/1/13/836


Memantine ratiopharm


Norway


7.5.2018




EU/1/13/838


AUBAGIO


Iceland


15.6.2018




EU/1/13/838


AUBAGIO


Liechtenstein


30.6.2018




EU/1/13/838


AUBAGIO


Norway


21.6.2018




EU/1/13/839


Iclusig


Iceland


23.2.2018




EU/1/13/839


Iclusig


Liechtenstein


28.2.2018




EU/1/13/839


Iclusig


Norway


20.2.2018




EU/1/13/840


HyQvia


Iceland


18.1.2018




EU/1/13/840


HyQvia


Liechtenstein


28.2.2018




EU/1/13/840


HyQvia


Norway


16.1.2018




EU/1/13/841


Spedra


Iceland


22.5.2018




EU/1/13/841


Spedra


Liechtenstein


30.6.2018




EU/1/13/841


Spedra


Norway


15.5.2018




EU/1/13/842


Incresync


Iceland


15.6.2018




EU/1/13/842


Incresync


Liechtenstein


30.6.2018




EU/1/13/843


Vipdomet


Iceland


15.6.2018




EU/1/13/843


Vipdomet


Liechtenstein


30.6.2018




EU/1/13/844


Vipidia


Iceland


15.6.2018




EU/1/13/844


Vipidia


Liechtenstein


30.6.2018




EU/1/13/844


Vipidia


Norway


26.6.2018




EU/1/13/845


Imatinib Accord


Iceland


16.5.2018




EU/1/13/845


Imatinib Accord


Liechtenstein


30.6.2018




EU/1/13/845


Imatinib Accord


Norway


4.5.2018




EU/1/13/846


Xtandi


Iceland


23.2.2018




EU/1/13/846


Xtandi


Liechtenstein


28.2.2018




EU/1/13/846


Xtandi


Norway


2.3.2018




EU/1/13/851


Lojuxta


Iceland


22.5.2018




EU/1/13/851


Lojuxta


Liechtenstein


30.6.2018




EU/1/13/851


Lojuxta


Norway


23.5.2018




EU/1/13/852


Atosiban SUN


Iceland


15.6.2018




EU/1/13/852


Atosiban SUN


Liechtenstein


30.6.2018




EU/1/13/852


Atosiban SUN


Norway


25.6.2018




EU/1/13/853


Remsima


Iceland


29.6.2018




EU/1/13/853


Remsima


Liechtenstein


30.6.2018




EU/1/13/854


Inflectra


Iceland


28.6.2018




EU/1/13/854


Inflectra


Liechtenstein


30.6.2018




EU/1/13/855


IMVANEX


Iceland


22.5.2018




EU/1/13/855


Imvanex


Liechtenstein


30.6.2018




EU/1/13/855


Imvanex


Norway


15.5.2018




EU/1/13/856


Lonquex


Iceland


25.5.2018




EU/1/13/856


Lonquex


Liechtenstein


30.6.2018




EU/1/13/856


Lonquex


Norway


25.5.2018




EU/1/13/857


Voncento


Iceland


23.5.2018




EU/1/13/857


Voncento


Liechtenstein


30.6.2018




EU/1/13/857


Voncento


Norway


23.5.2018




EU/1/13/858


Stivarga


Iceland


30.5.2018




EU/1/13/858


Stivarga


Liechtenstein


30.6.2018




EU/1/13/858


Stivarga


Norway


31.5.2018




EU/1/13/862


Ultibro Breezhaler


Iceland


30.5.2018




EU/1/13/862


Ultibro Breezhaler


Liechtenstein


30.6.2018




EU/1/13/862


Ultibro Breezhaler


Norway


21.6.2018




EU/1/13/863


Xoterna Breezhaler


Iceland


30.5.2018




EU/1/13/863


Xoterna Breezhaler


Liechtenstein


30.6.2018




EU/1/13/863


Xoterna Breezhaler


Norway


21.6.2018




EU/1/13/865


Tafinlar


Iceland


28.5.2018




EU/1/13/865


Tafinlar


Liechtenstein


30.6.2018




EU/1/13/865


Tafinlar


Norway


18.5.2018




EU/1/13/866


Cholib


Iceland


15.6.2018




EU/1/13/866


Cholib


Liechtenstein


30.6.2018




EU/1/13/866


Cholib


Norway


16.5.2018




EU/1/13/871


Ovaleap


Iceland


29.5.2018




EU/1/13/871


Ovaleap


Liechtenstein


30.6.2018




EU/1/13/871


Ovaleap


Norway


16.5.2018




EU/1/13/873


Xofigo


Iceland


29.6.2018




EU/1/13/873


Xofigo


Liechtenstein


30.6.2018




EU/1/13/875


Deltyba


Iceland


16.5.2018




EU/1/13/875


Deltyba


Liechtenstein


30.6.2018




EU/1/13/875


Deltyba


Norway


16.5.2018




EU/1/13/876


Imatinib medac


Iceland


16.5.2018




EU/1/13/876


Imatinib Medac


Liechtenstein


30.6.2018




EU/1/13/876


Imatinib medac


Norway


4.5.2018




EU/1/13/879


Giotrif


Iceland


29.5.2018




EU/1/13/879


Giotrif


Liechtenstein


30.6.2018




EU/1/13/879


Giotrif


Norway


24.5.2018




EU/1/13/890


Cometriq


Iceland


18.1.2018




EU/1/13/890


Cometriq


Liechtenstein


30.4.2018




EU/1/13/890


Cometriq


Norway


17.1.2018




EU/1/13/901


Sirturo


Iceland


14.3.2018




EU/1/13/901


Sirturo


Norway


22.3.2018




EU/1/14/987


Holoclar


Norway


4.1.2018




EU/1/15/1047


Blincyto


Iceland


16.5.2018




EU/1/15/1047


Blincyto


Norway


26.6.2018




EU/1/15/1078


Natpar


Iceland


16.5.2018




EU/1/15/1078


Natpar


Liechtenstein


30.6.2018




EU/1/16/1089


Pandemic influenza vaccine H5N1 AstraZeneca


Iceland


12.4.2018




EU/1/16/1089


Pandemic influenza vaccine H5N1 Astra Zeneca


Liechtenstein


30.4.2018




EU/1/16/1089


Pandemic influenza vaccine H5N1


Norway


10.4.2018




EU/2/12/145


Kexxtone


Iceland


4.1.2018




EU/2/12/146


Semintra


Iceland


22.1.2018




EU/2/12/146


Semintra


Liechtenstein


28.2.2018




EU/2/12/146


Semintra


Norway


30.1.2018




EU/2/13/148


Meloxidolor


Iceland


16.5.2018




EU/2/13/148


Meloxidolor


Liechtenstein


30.6.2018




EU/2/13/148


Meloxidolor


Norway


16.5.2018




EU/2/13/149


ECOPORC SHIGA


Iceland


13.4.2018




EU/2/13/149


ECOPORC SHIGA


Liechtenstein


30.4.2018




EU/2/13/149


ECOPORC SHIGA


Norway


20.4.2018




EU/2/13/150


Oncept IL-2


Iceland


26.3.2018




EU/2/13/150


Oncept IL-2


Liechtenstein


30.4.2018




EU/2/13/150


Oncept IL-2


Norway


19.4.2018




EU/2/13/151


Equilis West Nile


Iceland


15.5.2018




EU/2/13/151


Equilis West Nile


Liechtenstein


30.4.2018




EU/2/13/151


Equilis West Nile


Norway


7.5.2018




EU/2/13/152


ProZinc


Iceland


3.5.2018




EU/2/13/152


ProZinc


Liechtenstein


30.4.2018




EU/2/13/152


ProZinc


Norway


7.5.2018




EU/2/13/153


Aftovaxpur Doe


Iceland


21.6.2018




EU/2/13/153


Aftovaxpur Doe


Liechtenstein


30.6.2018




EU/2/13/153


Aftovaxpur Doe


Norway


28.6.2018









ANNEX III
List of extended marketing authorisations
The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January — 30 June 2018:








EU-Number


Product


Country


Date of authorisation




EU/1/10/636/008


Daxas


Iceland


22.5.2018




EU/1/10/636/008


Daxas


Norway


23.4.2018




EU/1/11/700/003-007


Benlysta


Iceland


10.1.2018




EU/1/11/700/003-007


Benlysta


Norway


22.1.2018




EU/1/11/710/016


Votubia


Iceland


18.6.2018




EU/1/11/710/016


Votubia


Norway


8.6.2018




EU/1/13/818/006-007


Bosulif


Iceland


30.5.2018




EU/1/13/818/006-007


Bosulif


Norway


29.5.2018




EU/1/14/936/005-007


Nuwiq


Iceland


11.4.2018




EU/1/14/936/005-007


Nuwiq


Norway


20.4.2018




EU/1/14/945/003-006


IMBRUVICA


Norway


29.6.2018




EU/1/14/959/002-005


Lynparza


Iceland


24.5.2018




EU/1/14/959/002-005


Lynparza


Norway


8.5.2018




EU/1/15/1019/002


Bortezomib Accord


Iceland


18.6.2018




EU/1/15/1019/002


Bortezomib Accord


Norway


14.6.2018




EU/1/15/1059/005


Orkambi


Iceland


18.1.2018




EU/1/15/1059/005


Orkambi


Norway


17.1.2018




EU/1/15/1070/002


Oncaspar


Norway


3.1.2018




EU/2/12/146/003


Semintra


Iceland


25.5.2018




EU/2/12/146/003


Semintra


Norway


24.5.2018









ANNEX IV
List of withdrawn marketing authorisations
The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January — 30 June 2018:








EU-Number


Product


Country


Date of withdrawal




EU/1/04/289


Angiox


Liechtenstein


30.6.2018




EU/1/06/368


Insulin Human Winthrop


Iceland


17.1.2018




EU/1/06/368


Insulin Human Winthrop


Liechtenstein


30.4.2018




EU/1/06/368


Insulin Human Winthrop


Norway


22.1.2018




EU/1/07/394


Optaflu


Iceland


12.2.2018




EU/1/08/507


Idflu


Iceland


11.4.2018




EU/1/08/507


IDflu


Liechtenstein


30.4.2018




EU/1/08/507


IDflu


Norway


5.4.2018




EU/1/11/705


Vibativ


Iceland


11.4.2018




EU/1/11/705


Vibativ


Norway


6.4.2018




EU/1/11/666


Libertek


Iceland


17.1.2018




EU/1/11/666


Libertek


Liechtenstein


28.2.2018




EU/1/11/666


Libertek


Norway


22.1.2018




EU/1/11/668


Daliresp


Iceland


17.1.2018




EU/1/11/668


Daliresp


Liechtenstein


28.2.2018




EU/1/11/668


Daliresp


Norway


22.1.2018




EU/1/12/772


Zoledronic acid Teva Pharma


Iceland


7.2.2018




EU/1/12/772


Zoledronsäure Teva Pharma


Liechtenstein


28.2.2018




EU/1/12/722


Zoledronic acid Teva Pharma


Norway


7.2.2018




EU/1/14/924


Olysio


Iceland


1.5.2018




EU/1/14/924


Olysio


Norway


1.5.2018




EU/1/14/985


Raplixa


Iceland


11.4.2018




EU/1/14/985


Raplixa


Norway


12.4.2018




EU/1/16/1107


Zinbryta


Iceland


25.4.2018




EU/1/16/1107


Zinbryta


Liechtenstein


30.4.2018




EU/1/16/1107


Zinbryta


Norway


19.4.2018




EU/1/17/1243


Imatinib Teva B.V.


Iceland


24.5.2018




EU/1/17/1243


Imatinib Teva B.V.


Norway


8.5.2018




EU/1/97/032


LeukoScan


Iceland


9.2.2018




EU/1/97/032


LeukoScan


Liechtenstein


28.2.2018




EU/1/97/032


LeukoScan


Norway


21.2.2018




EU/2/07/077


Meloxivet


Iceland


15.6.2018




EU/2/07/077


Meloxivet


Liechtenstein


30.6.2018




EU/2/07/077


Meloxivet


Norway


25.5.2018




EU/2/09/094


BTVPUR AISap 8


Iceland


24.5.2018




EU/2/09/094


BTVPUR AlSap 8


Norway


6.6.2018




EU/2/10/112


BTVPUR ALSap 1


Iceland


24.5.2018




EU/2/10/112


BTVPUR AlSap 1


Norway


6.6.2018




EU/2/11/125


Certifect


Iceland


23.5.2018




EU/2/11/125


CERTIFECT


Liechtenstein


30.6.2018




EU/2/11/125


CERTIFECT


Norway


22.6.2018









ANNEX V
List of suspended marketing authorisations
The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January — 30 June 2018:








EU-Number


Product


Country


Date of suspension